Search

Your search keyword '"Agarwala S"' showing total 1,283 results
Start Over Author "Agarwala S"
1,283 results on '"Agarwala S"'

2. Cystic neuroblastoma in an older child

Author

Agarwala S and Bhatnagar V

Subjects
Cystic neuroblastoma, outcome, postnatal diagnosis, Pediatrics, RJ1-570, Surgery, RD1-811
Abstract

Cystic neuroblastoma presenting beyond the neonatal period is rare and seems to have a different presentation and outcome as compared to those diagnosed in the antenatal and perinatal period. Presented herein is a case of cystic neuroblastoma diagnosed in a 9-year-old girl who had a poor outcome despite complete excision, aggressive chemotherapy and radiation therapy.

Published
2005

4. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients

Author

Algazi, A, Bhatia, S, Agarwala, S, Molina, M, Lewis, K, Faries, M, Fong, L, Levine, LP, Franco, M, Oglesby, A, Ballesteros-Merino, C, Bifulco, CB, Fox, BA, Bannavong, D, Talia, R, Browning, E, Le, MH, Pierce, RH, Gargosky, S, Tsai, KK, Twitty, C, and Daud, AI

Subjects
Vaccine Related, Immunization, Clinical Trials and Supportive Activities, Clinical Research, Genetics, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Electroporation, Humans, Immunity, Interleukin-12, Melanoma, Plasmids, Prospective Studies, Skin Neoplasms, Immunotherapy, IL-12, Tavokinogene telseplasmid, intratumoral, melanoma, electroporation, cytokine, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundInterleukin 12 (IL-12) is a pivotal regulator of innate and adaptive immunity. We conducted a prospective open-label, phase II clinical trial of electroporated plasmid IL-12 in advanced melanoma patients (NCT01502293).Patients and methodsPatients with stage III/IV melanoma were treated intratumorally with plasmid encoding IL-12 (tavokinogene telseplasmid; tavo), 0.5 mg/ml followed by electroporation (six pulses, 1500 V/cm) on days 1, 5, and 8 every 90 days in the main study and additional patients were treated in two alternative schedule exploration cohorts. Correlative analyses for programmed death-ligand 1 (PD-L1), flow cytometry to assess changes in immune cell subsets, and analysis of immune-related gene expression were carried out on pre- and post-treatment samples from study patients, as well as from additional patients treated during exploration of additional dosing schedules beyond the pre-specified protocol dosing schedule. Response was measured by study-specific criteria to maximize detection of latent and potentially transient immune responses in patients with multiple skin lesions and toxicities were graded by the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).ResultsThe objective overall response rate was 35.7% in the main study (29.8% in all cohorts), with a complete response rate of 17.9% (10.6% in all cohorts). The median progression-free survival in the main study was 3.7 months while the median overall survival was not reached at a median follow up of 29.7 months. A total of 46% of patients in all cohorts with uninjected lesions experienced regression of at least one of these lesions and 25% had a net regression of all untreated lesions. Transcriptomic and immunohistochemistry analysis showed that immune activation and co-stimulatory transcripts were up-regulated but there was also increased adaptive immune resistance.ConclusionsIntratumoral Tavo was well tolerated and led to systemic immune responses in advanced melanoma patients. While tumor regression and increased immune infiltration were observed in treated as well as untreated/distal lesions, adaptive immune resistance limited the response.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results